Word Matters - PowerPoint PPT Presentation

1 / 114
About This Presentation
Title:

Word Matters

Description:

... The diagnosis of Grave s disease in this case ... neither post-mortem studies nor ... Ivy Editing Leptin and leptin receptor gene polymorphism ... – PowerPoint PPT presentation

Number of Views:131
Avg rating:3.0/5.0
Slides: 115
Provided by: Office390
Category:

less

Transcript and Presenter's Notes

Title: Word Matters


1
(No Transcript)
2
Word Matters - An introduction to medical
writing Kehong Zhang, MD, PhD Editorial
Director, Ivy Editing - China Assistant
Professor, Harvard Medical School
(2003-2007) Tel 021-61390110 E-mail
paper_at_theivyediting.com Website
www.theivyediting.com
3
Ross Baldessarini, MD, DSc Professor, Harvard
Medical School Editorial Advisor, Ivy Editing
What is a manuscript?
E-mail paper_at_theivyediting.com
Tel 021-61390110
4
James ODonnell, PhD Professor, West Virginia
Univ Editorial Advisor, Ivy Editing
A manuscript is - a product for sale
E-mail paper_at_theivyediting.com
Tel 021-61390110
5
Bryan Hurley, PhD Assistant Professor, Harvard
Medical School Group Leader - immunology, Ivy
Editing
A manuscript is - a product for sale - a
girl hunting for a husband
E-mail paper_at_theivyediting.com
Tel 021-61390110
6
Arne Nystuen, PhD Assistant Professor, Univ. of
Nebraska Group Leader - genetics, Ivy Editing
Leptin and leptin receptor gene polymorphism in
obesity a combination effect in Chinese
population
The Path of Misery - Obesity - Obes Metab -
Milan
E-mail paper_at_theivyediting.com
Tel 021-61390110
7
Kai Sonntag, MD, PhD Assistant Professor, Harvard
Medical School Group Leader - neuroscience, Ivy
Editing
Multiple genes interact with environmental
provocations to modify obesity risk. Leptin, a
important signal in the regulation of
adipose-tissue mass, operate by inhibiting food
intake and stimulating energy expenditure.The
biologic activities of leptin are carried out
through selective binding of leptin receptor.
E-mail paper_at_theivyediting.com
Tel 021-61390110
8
Anne ODonnell, MD, PhD Boston Children
Hospital Group Leader - clinical studies, Ivy
Editing
Multiple genes interact with environmental
provocations to modify obesity risk. Leptin, a
important signal in the regulation of
adipose-tissue mass, operate by inhibiting food
intake and stimulating energy expenditure.The
biologic activities of leptin are carried out
through selective binding of leptin receptor.
E-mail paper_at_theivyediting.com
Tel 021-61390110
9
Bo Cui, MD, PhD Deputy Editor-in-Chief, J Biomed
Res Group Leader - tumor biology, Ivy Editing
Multiple genes interact with environmental
provocations to modify obesity risk. Leptin, a
important signal in the regulation of
adipose-tissue mass, operate by inhibiting food
intake and stimulating energy expenditure.The
biologic activities of leptin are carried out
through selective binding of leptin receptor.
E-mail paper_at_theivyediting.com
Tel 021-61390110
10
Jesse Potash, PhD Free-lance, formerly an editor
at Nature Methods Group Leader - cell biology,
Ivy Editing
Multiple genes interact with environmental
provocations to modify obesity risk. Leptin, a
important signal in the regulation of
adipose-tissue mass, operate by inhibiting food
intake and stimulating energy expenditure.The
biologic activities of leptin are carried out
through selective binding of leptin receptor.
E-mail paper_at_theivyediting.com
Tel 021-61390110
11
Ross Baldessarini, MD, DSc Professor, Harvard
Medical School Editorial Advisor, Ivy Editing
E-mail paper_at_theivyediting.com
Tel 021-61390110
12
James ODonnell, PhD Professor, West Virginia
Univ Editorial Advisor, Ivy Editing
The barriers - English language?
E-mail paper_at_theivyediting.com
Tel 021-61390110
13
Bryan Hurley, PhD Assistant Professor, Harvard
Medical School Group Leader - immunology, Ivy
Editing
????
E-mail paper_at_theivyediting.com
Tel 021-61390110
14
Arne Nystuen, PhD Assistant Professor, Univ. of
Nebraska Group Leader - genetics, Ivy Editing
non-ferrous metals
E-mail paper_at_theivyediting.com
Tel 021-61390110
15
Kai Sonntag, MD, PhD Assistant Professor, Harvard
Medical School Group Leader - neuroscience, Ivy
Editing
The barriers - English language? - Beyond
language
E-mail paper_at_theivyediting.com
Tel 021-61390110
16
Anne ODonnell, MD, PhD Boston Children
Hospital Group Leader - clinical studies, Ivy
Editing
Title Idarubicin vs. daunorubicin in combination
with Ara-C as induction treatment for de novo
acute myeloid leukemia
E-mail paper_at_theivyediting.com
Tel 021-61390110
17
Bo Cui, MD, PhD Deputy Editor-in-Chief, J Biomed
Res Group Leader - tumor biology, Ivy Editing
Methods Medical records of 242 AML patients
receiving Ara-C plus idarubicin or daunorubicin
as induction treatment between 2002 and 2011 were
reviewed.
E-mail paper_at_theivyediting.com
Tel 021-61390110
18
Jesse Potash, PhD Free-lance, formerly an editor
at Nature Methods Group Leader - cell biology,
Ivy Editing
Methods Medical records of 242 AML patients
receiving Ara-C plus idarubicin or daunorubicin
as induction treatment between 2002 and 2011 were
reviewed. . Written informed consent was
obtained from all patients.
E-mail paper_at_theivyediting.com
Tel 021-61390110
19
Ross Baldessarini, MD, DSc Professor, Harvard
Medical School Editorial Advisor, Ivy Editing
Lesson 1 - Use your brain
E-mail paper_at_theivyediting.com
Tel 021-61390110
20
James ODonnell, PhD Professor, West Virginia
Univ Editorial Advisor, Ivy Editing
Results The levels of uric acid after urikase
treatment were significantly lower as compared to
the baseline level before the treatment (plt0.05).

E-mail paper_at_theivyediting.com
Tel 021-61390110
21
Bryan Hurley, PhD Assistant Professor, Harvard
Medical School Group Leader - immunology, Ivy
Editing
Results The levels of uric acid after urikase
treatment were significantly lower as compared to
the baseline level before the treatment (plt0.05).

E-mail paper_at_theivyediting.com
Tel 021-61390110
22
Arne Nystuen, PhD Assistant Professor, Univ. of
Nebraska Group Leader - genetics, Ivy Editing
The levels of uric acid after urikase treatment
were significantly lower as compared to the
baseline level before the treatment (plt0.05).
Urikase treatment decreased serum uric acid
(plt0.05 vs. the baseline).
E-mail paper_at_theivyediting.com
Tel 021-61390110
23
Kai Sonntag, MD, PhD Assistant Professor, Harvard
Medical School Group Leader - neuroscience, Ivy
Editing
The levels of uric acid after urikase treatment
were significantly lower as compared to the
baseline level before the treatment (plt0.05).
Urikase treatment decreased serum uric acid
(plt0.05 vs. the baseline).
E-mail paper_at_theivyediting.com
Tel 021-61390110
24
Anne ODonnell, MD, PhD Boston Children
Hospital Group Leader - clinical studies, Ivy
Editing
  • Lesson 2
  • Keep it simple

E-mail paper_at_theivyediting.com
Tel 021-61390110
25
Bo Cui, MD, PhD Deputy Editor-in-Chief, J Biomed
Res Group Leader - tumor biology, Ivy Editing
International Journal of Radiation Oncology
Biology Physics, 67888-896, 2007 Due to the
complex molecular pathogenesis of glioblastoma
multiforme, therapeutic strategies are evolving
from cytotoxic therapies to molecular approaches
which target specific signaling cascades that
promote tumor growth such as cyclooxygenase-2
(COX-2), a rate-limiting enzyme in conversion of
arachidonic acid into prostaglandins.
E-mail paper_at_theivyediting.com
Tel 021-61390110
26
Jesse Potash, PhD Free-lance, formerly an editor
at Nature Methods Group Leader - cell biology,
Ivy Editing
International Journal of Radiation Oncology
Biology Physics, 67888-896, 2007 Due to the
complex molecular pathogenesis of glioblastoma
multiforme, therapeutic strategies are evolving
from cytotoxic therapies to molecular approaches
which target specific signaling cascades that
promote tumor growth such as cyclooxygenase-2
(COX-2), a rate-limiting enzyme in conversion of
arachidonic acid into prostaglandins.
E-mail paper_at_theivyediting.com
Tel 021-61390110
27
Ross Baldessarini, MD, DSc Professor, Harvard
Medical School Editorial Advisor, Ivy Editing
International Journal of Radiation Oncology
Biology Physics, 67888-896, 2007 Due to the
complex molecular pathogenesis of glioblastoma
multiforme, therapeutic strategies are evolving
from cytotoxic therapies to molecular approaches
which target specific signaling cascades that
promote tumor growth such as cyclooxygenase-2
(COX-2), a rate-limiting enzyme in conversion of
arachidonic acid into prostaglandins.
E-mail paper_at_theivyediting.com
Tel 021-61390110
28
James ODonnell, PhD Professor, West Virginia
Univ Editorial Advisor, Ivy Editing
International Journal of Radiation Oncology
Biology Physics, 67888-896, 2007 Due to the
complex molecular pathogenesis of glioblastoma
multiforme, therapeutic strategies are evolving
from cytotoxic therapies to molecular approaches
which target specific signaling cascades that
promote tumor growth such as cyclooxygenase-2
(COX-2), a rate-limiting enzyme in conversion of
arachidonic acid into prostaglandins.
E-mail paper_at_theivyediting.com
Tel 021-61390110
29
Bryan Hurley, PhD Assistant Professor, Harvard
Medical School Group Leader - immunology, Ivy
Editing
International Journal of Radiation Oncology
Biology Physics, 67888-896, 2007 Due to the
complex molecular pathogenesis of glioblastoma
multiforme, therapeutic strategies are evolving
from cytotoxic therapies to molecular approaches
which target specific signaling cascades that
promote tumor growth such as cyclooxygenase-2
(COX-2), a rate-limiting enzyme in conversion of
arachidonic acid into prostaglandins.
E-mail paper_at_theivyediting.com
Tel 021-61390110
30
Arne Nystuen, PhD Assistant Professor, Univ. of
Nebraska Group Leader - genetics, Ivy Editing
International Journal of Radiation Oncology
Biology Physics, 67888-896, 2007 Due to the
complex molecular pathogenesis of glioblastoma
multiforme, therapeutic strategies are evolving
from cytotoxic therapies to molecular approaches
which target specific signaling cascades that
promote tumor growth such as cyclooxygenase-2
(COX-2), a rate-limiting enzyme in conversion of
arachidonic acid into prostaglandins.
E-mail paper_at_theivyediting.com
Tel 021-61390110
31
Kai Sonntag, MD, PhD Assistant Professor, Harvard
Medical School Group Leader - neuroscience, Ivy
Editing
International Journal of Radiation Oncology
Biology Physics, 67888-896, 2007 Due to the
complex molecular pathogenesis of glioblastoma
multiforme, therapeutic strategies are evolving
from cytotoxic therapies to molecular approaches
which target specific signaling cascades that
promote tumor growth such as cyclooxygenase-2
(COX-2), a rate-limiting enzyme in conversion of
arachidonic acid into prostaglandins.
E-mail paper_at_theivyediting.com
Tel 021-61390110
32
Anne ODonnell, MD, PhD Boston Children
Hospital Group Leader - clinical studies, Ivy
Editing
International Journal of Radiation Oncology
Biology Physics, 67888-896, 2007 Due to the
complex molecular pathogenesis of glioblastoma
multiforme, therapeutic strategies are evolving
from cytotoxic therapies to molecular approaches
which target specific signaling cascades that
promote tumor growth such as cyclooxygenase-2
(COX-2), a rate-limiting enzyme in conversion of
arachidonic acid into prostaglandins.
E-mail paper_at_theivyediting.com
Tel 021-61390110
33
Bo Cui, MD, PhD Deputy Editor-in-Chief, J Biomed
Res Group Leader - tumor biology, Ivy Editing
Despite of the complex molecular pathogenesis of
glioblastoma multiforme, therapeutic strategy is
evolving from cytotoxic to molecular approaches.
E-mail paper_at_theivyediting.com
Tel 021-61390110
34
Jesse Potash, PhD Free-lance, formerly an editor
at Nature Methods Group Leader - cell biology,
Ivy Editing
Despite of the complex molecular pathogenesis of
glioblastoma multiforme, therapeutic strategy is
evolving from cytotoxic to molecular
approaches. Activation of cyclooxygenase-2
(COX-2), the rate-limiting enzyme in
prostaglandin biosynthesis, promotes tumor
growth, and therefore represents a promising
target for intervention.
E-mail paper_at_theivyediting.com
Tel 021-61390110
35
Ross Baldessarini, MD, DSc Professor, Harvard
Medical School Editorial Advisor, Ivy Editing
Lesson 3 - One thing at a time
E-mail paper_at_theivyediting.com
Tel 021-61390110
36
James ODonnell, PhD Professor, West Virginia
Univ Editorial Advisor, Ivy Editing
Results IL-1 kidney level was significantly
different between the H and M groups compared
with the C group. However, the L group was not
statistically different from the C group.
E-mail paper_at_theivyediting.com
Tel 021-61390110
37
Bryan Hurley, PhD Assistant Professor, Harvard
Medical School Group Leader - immunology, Ivy
Editing
Results IL-1 kidney level was significantly
different between the H and M groups compared
with the C group. However, the L group was not
statistically different from the C group.
E-mail paper_at_theivyediting.com
Tel 021-61390110
38
Arne Nystuen, PhD Assistant Professor, Univ. of
Nebraska Group Leader - genetics, Ivy Editing
Methods The control group (C group) received
vehicle. The remaining 3 groups received
metformin at low (L group 62.5 mg/kg/d), middle
(M group 125 mg/kg/d), and high (H group 250
mg/kg/d) doses, respectively.
E-mail paper_at_theivyediting.com
Tel 021-61390110
39
Kai Sonntag, MD, PhD Assistant Professor, Harvard
Medical School Group Leader - neuroscience, Ivy
Editing
Results IL-1 kidney level was significantly
different between the H and M groups compared
with the C group. However, the L group was not
statistically different from the C group.
E-mail paper_at_theivyediting.com
Tel 021-61390110
40
Anne ODonnell, MD, PhD Boston Children
Hospital Group Leader - clinical studies, Ivy
Editing
Results IL-1 kidney level was significantly
different between the H and M groups compared
with the C group. However, the L group was not
statistically different from the C group.
E-mail paper_at_theivyediting.com
Tel 021-61390110
41
Bo Cui, MD, PhD Deputy Editor-in-Chief, J Biomed
Res Group Leader - tumor biology, Ivy Editing
IL-1 kidney level was significantly different
between the H and M groups compared with the C
group. However, the L group was not statistically
different from the C group.
Chronic metformin treatment decreased kidney IL-1
level in diabetic rats at 125 and 250 mg/kg/d
(plt0.05 vs. vehicle control for both), but not at
a lower dose of 62.5 mg/kg/d.
E-mail paper_at_theivyediting.com
Tel 021-61390110
42
Jesse Potash, PhD Free-lance, formerly an editor
at Nature Methods Group Leader - cell biology,
Ivy Editing
IL-1 kidney level was significantly different
between the H and M groups compared with the C
group. However, the L group was not statistically
different from the C group.
Chronic metformin treatment decreased kidney IL-1
level in diabetic rats at 125 and 250 mg/kg/d
(plt0.05 vs. vehicle control for both), but not at
a lower dose of 62.5 mg/kg/d.
E-mail paper_at_theivyediting.com
Tel 021-61390110
43
Ross Baldessarini, MD, DSc Professor, Harvard
Medical School Editorial Advisor, Ivy Editing
Lesson 4 - Make it easy for the reviewers
E-mail paper_at_theivyediting.com
Tel 021-61390110
44
James ODonnell, PhD Professor, West Virginia
Univ Editorial Advisor, Ivy Editing
title Effects of dopamine D4 receptor antagonists
in a primate model of social interaction
E-mail paper_at_theivyediting.com
Tel 021-61390110
45
Bryan Hurley, PhD Assistant Professor, Harvard
Medical School Group Leader - immunology, Ivy
Editing
The neurotransmitter dopamine produces its action
via five G-protein coupled receptors. These
receptor could be classified into two
subfamilies the D1-like and D2-like receptors.
E-mail paper_at_theivyediting.com
Tel 021-61390110
46
Arne Nystuen, PhD Assistant Professor, Univ. of
Nebraska Group Leader - genetics, Ivy Editing
The neurotransmitter dopamine produces its action
via five G-protein coupled receptors. These
receptor could be classified into two
subfamilies the D1-like and D2-like receptors.

E-mail paper_at_theivyediting.com
Tel 021-61390110
47
Kai Sonntag, MD, PhD Assistant Professor, Harvard
Medical School Group Leader - neuroscience, Ivy
Editing
The neurotransmitter dopamine produces its action
via five G-protein coupled receptors. These
receptor could be classified into two
subfamilies the D1-like and D2-like receptors.
Schizophrenia is a devastating developmental
disease that affects approximately 1 of the
overall population.
E-mail paper_at_theivyediting.com
Tel 021-61390110
48
Anne ODonnell, MD, PhD Boston Children
Hospital Group Leader - clinical studies, Ivy
Editing
The neurotransmitter dopamine produces its action
via five G-protein coupled receptors. These
receptor could be classified into two
subfamilies the D1-like and D2-like receptors.
Schizophrenia is a devastating developmental
disease that affects approximately 1 of the
overall population.
E-mail paper_at_theivyediting.com
Tel 021-61390110
49
Bo Cui, MD, PhD Deputy Editor-in-Chief, J Biomed
Res Group Leader - tumor biology, Ivy Editing
The neurotransmitter dopamine produces its action
via five G-protein coupled receptors. These
receptor could be classified into two
subfamilies the D1-like and D2-like receptors.
Schizophrenia is a devastating developmental
disease that affects approximately 1 of the
overall population. Despite of extensive
research effort, the molecular mechanisms
underlying schizophrenia remains poorly
understood.
E-mail paper_at_theivyediting.com
Tel 021-61390110
50
Jesse Potash, PhD Free-lance, formerly an editor
at Nature Methods Group Leader - cell biology,
Ivy Editing
The neurotransmitter dopamine produces its action
via five G-protein coupled receptors. These
receptor could be classified into two
subfamilies the D1-like and D2-like receptors.
Schizophrenia is a devastating developmental
disease that affects approximately 1 of the
overall population. Despite of extensive
research effort, the molecular mechanisms
underlying schizophrenia remains poorly
understood. Dysfunction of D2 receptors is the
prevailing hypothesis.
E-mail paper_at_theivyediting.com
Tel 021-61390110
51
Ross Baldessarini, MD, DSc Professor, Harvard
Medical School Editorial Advisor, Ivy Editing
The neurotransmitter dopamine produces its action
via five G-protein coupled receptors. These
receptor could be classified into two
subfamilies the D1-like and D2-like receptors.
Schizophrenia is a devastating developmental
disease that affects approximately 1 of the
overall population. Despite of extensive
research effort, the molecular mechanisms
underlying schizophrenia remains poorly
understood. Dysfunction of D2 receptors is the
prevailing hypothesis. However, recent evidence
suggested that D4 receptor is also involved.
E-mail paper_at_theivyediting.com
Tel 021-61390110
52
James ODonnell, PhD Professor, West Virginia
Univ Editorial Advisor, Ivy Editing
The neurotransmitter dopamine produces its action
via five G-protein coupled receptors. These
receptor could be classified into two
subfamilies the D1-like and D2-like receptors.
Schizophrenia is a devastating developmental
disease that affects approximately 1 of the
overall population. Despite of extensive
research effort, the molecular mechanisms
underlying schizophrenia remains poorly
understood. Dysfunction of D2 receptors is the
prevailing hypothesis. However, recent evidence
suggested that D4 receptor is also involved. In
this study, we examined potential effects of
on social interaction ..
E-mail paper_at_theivyediting.com
Tel 021-61390110
53
Bryan Hurley, PhD Assistant Professor, Harvard
Medical School Group Leader - immunology, Ivy
Editing
About dopamine receptors About schizophrenia
Why study D4 on social interaction?
E-mail paper_at_theivyediting.com
Tel 021-61390110
54
Arne Nystuen, PhD Assistant Professor, Univ. of
Nebraska Group Leader - genetics, Ivy Editing
Why study D4? 1) Dysfunction of D2 receptors is
the prevailing hypothesis. 2) However, recent
evidence suggested that D4 receptor is also
involved.
E-mail paper_at_theivyediting.com
Tel 021-61390110
55
Kai Sonntag, MD, PhD Assistant Professor, Harvard
Medical School Group Leader - neuroscience, Ivy
Editing
Dysfunction of D2 receptors is the prevailing
hypothesis.
E-mail paper_at_theivyediting.com
Tel 021-61390110
56
Anne ODonnell, MD, PhD Boston Children
Hospital Group Leader - clinical studies, Ivy
Editing
Dysfunction of D2 receptors is the prevailing
hypothesis.
Most antipsychotic agents, particularly the
first-generation neuroleptics, are dopamine D2
receptor antagonsists.
E-mail paper_at_theivyediting.com
Tel 021-61390110
57
Bo Cui, MD, PhD Deputy Editor-in-Chief, J Biomed
Res Group Leader - tumor biology, Ivy Editing
Dysfunction of D2 receptors is the prevailing
hypothesis.
Most antipsychotic agents, particularly the
first-generation neuroleptics, are dopamine D2
receptor antagonsists. These drugs could
alleviate positive symptoms (e.g., hallucination).
E-mail paper_at_theivyediting.com
Tel 021-61390110
58
Jesse Potash, PhD Free-lance, formerly an editor
at Nature Methods Group Leader - cell biology,
Ivy Editing
Why study D4? 1) Dysfunction of D2 receptors is
the prevailing hypothesis.
the missing link?? 2) However, recent
evidence suggested that D4 receptor is also
involved.
E-mail paper_at_theivyediting.com
Tel 021-61390110
59
Ross Baldessarini, MD, DSc Professor, Harvard
Medical School Editorial Advisor, Ivy Editing
Most antipsychotic agents, particularly the
first-generation neuroleptics, are dopamine D2
receptor antagonsists. These drugs could
alleviate positive symptoms (e.g.,
hallucination), but generally do not affect
negative symptoms (e.g., social withdrawal).
E-mail paper_at_theivyediting.com
Tel 021-61390110
60
James ODonnell, PhD Professor, West Virginia
Univ Editorial Advisor, Ivy Editing
Most antipsychotic agents, particularly the
first-generation neuroleptics, are dopamine D2
receptor antagonsists. These drugs could
alleviate positive symptoms (e.g.,
hallucination), but generally do not affect
negative symptoms (e.g., social withdrawal).
Equally important, neither post-mortem studies
nor clinical imaging studies provided any
evidence for altered D2 receptor expression in
schizophrenic patients.
E-mail paper_at_theivyediting.com
Tel 021-61390110
61
Bryan Hurley, PhD Assistant Professor, Harvard
Medical School Group Leader - immunology, Ivy
Editing
Why study D4? 1) Dysfunction of D2 receptors is
the prevailing hypothesis. 2) However, recent
evidence suggested that D4 receptor is also
involved.
E-mail paper_at_theivyediting.com
Tel 021-61390110
62
Arne Nystuen, PhD Assistant Professor, Univ. of
Nebraska Group Leader - genetics, Ivy Editing
However, recent evidence suggested that D4
receptor is also involved.
Two recent post-mortem studies suggested that D4
receptor is over-expressed in the prefrontal
cortex of schizophrenic patients.
E-mail paper_at_theivyediting.com
Tel 021-61390110
63
Kai Sonntag, MD, PhD Assistant Professor, Harvard
Medical School Group Leader - neuroscience, Ivy
Editing
Two recent post-mortem studies suggested that D4
receptor is over-expressed in the prefrontal
cortex (PFC) of schizophrenic patients. Also,
some of the newer atypical antipsychotics (e.g.,
clozapine) have high affinity at the D4 receptor.
E-mail paper_at_theivyediting.com
Tel 021-61390110
64
Anne ODonnell, MD, PhD Boston Children
Hospital Group Leader - clinical studies, Ivy
Editing
  • Lesson 5
  • The key part must have
  • sufficient depth

E-mail paper_at_theivyediting.com
Tel 021-61390110
65
Bo Cui, MD, PhD Deputy Editor-in-Chief, J Biomed
Res Group Leader - tumor biology, Ivy Editing
About dopamine receptors About schizophrenia
Why study D4 on social interaction?
E-mail paper_at_theivyediting.com
Tel 021-61390110
66
Jesse Potash, PhD Free-lance, formerly an editor
at Nature Methods Group Leader - cell biology,
Ivy Editing
Lesson 6 - A manuscript is a story
E-mail paper_at_theivyediting.com
Tel 021-61390110
67
Ross Baldessarini, MD, DSc Professor, Harvard
Medical School Editorial Advisor, Ivy Editing
Lesson 6 - A manuscript is a story - It
needs to be plotted
E-mail paper_at_theivyediting.com
Tel 021-61390110
68
James ODonnell, PhD Professor, West Virginia
Univ Editorial Advisor, Ivy Editing
  • Lesson 6
  • - A manuscript is a story
  • It needs to be plotted
  • for a specific audience

E-mail paper_at_theivyediting.com
Tel 021-61390110
69
Bryan Hurley, PhD Assistant Professor, Harvard
Medical School Group Leader - immunology, Ivy
Editing
Effects of triptolide in an animal model of
rheumatoid arthritis
E-mail paper_at_theivyediting.com
Tel 021-61390110
70
Arne Nystuen, PhD Assistant Professor, Univ. of
Nebraska Group Leader - genetics, Ivy Editing
Effects of triptolide in an animal model of
rheumatoid arthritis
E-mail paper_at_theivyediting.com
Tel 021-61390110
71
Kai Sonntag, MD, PhD Assistant Professor, Harvard
Medical School Group Leader - neuroscience, Ivy
Editing
Effects of triptolide in an animal model of
rheumatoid arthritis
Triptolide attenuates joint inflammation and
renal damage in a rat model of rheumatoid
arthritis
E-mail paper_at_theivyediting.com
Tel 021-61390110
72
Anne ODonnell, MD, PhD Boston Children
Hospital Group Leader - clinical studies, Ivy
Editing
Effects of triptolide in an animal model of
rheumatoid arthritis
Triptolide attenuates joint inflammation and
renal damage in a rat model of rheumatoid
arthritis
E-mail paper_at_theivyediting.com
Tel 021-61390110
73
Bo Cui, MD, PhD Deputy Editor-in-Chief, J Biomed
Res Group Leader - tumor biology, Ivy Editing
Lesson 7 - Put key findings in the title
E-mail paper_at_theivyediting.com
Tel 021-61390110
74
Jesse Potash, PhD Free-lance, formerly an editor
at Nature Methods Group Leader - cell biology,
Ivy Editing
Rebuttal - an art of
negotiating
E-mail paper_at_theivyediting.com
Tel 021-61390110
75
Ross Baldessarini, MD, DSc Professor, Harvard
Medical School Editorial Advisor, Ivy Editing
The authors should have carried out a set of
experiments using siRNA to block the expression
of myc, and examine whether myc inhibition could
eliminate the effects of microRNA-21.
E-mail paper_at_theivyediting.com
Tel 021-61390110
76
James ODonnell, PhD Professor, West Virginia
Univ Editorial Advisor, Ivy Editing
title microRNA-21 induces multidrug resistance
in glioblastoma through up-regulation of myc
E-mail paper_at_theivyediting.com
Tel 021-61390110
77
Bryan Hurley, PhD Assistant Professor, Harvard
Medical School Group Leader - immunology, Ivy
Editing
Lesson 1 - Reviewer requests to add
experiments are rooted in the
manuscript
E-mail paper_at_theivyediting.com
Tel 021-61390110
78
Arne Nystuen, PhD Assistant Professor, Univ. of
Nebraska Group Leader - genetics, Ivy Editing
Reviewer Power analyses should be calculated
for the 2 SNPs based on the allele frequency and
effect size in previous reports. This could be
obtained from a representative study or from the
AlzGene.org meta-analyses.
E-mail paper_at_theivyediting.com
Tel 021-61390110
79
Kai Sonntag, MD, PhD Assistant Professor, Harvard
Medical School Group Leader - neuroscience, Ivy
Editing
Authors Power analyses have been calculated
using the allele frequency and effect size in
previous reports. Results are added to, and
discussed in the revised manuscript.
E-mail paper_at_theivyediting.com
Tel 021-61390110
80
Anne ODonnell, MD, PhD Boston Children
Hospital Group Leader - clinical studies, Ivy
Editing
Lesson 2 - Do not force the reviewer to
read your manuscript again
E-mail paper_at_theivyediting.com
Tel 021-61390110
81
Bo Cui, MD, PhD Deputy Editor-in-Chief, J Biomed
Res Group Leader - tumor biology, Ivy Editing
Reviewer The diagnosis of Graves disease in
this case should be supported by TSH receptor
antibody.
E-mail paper_at_theivyediting.com
Tel 021-61390110
82
Jesse Potash, PhD Free-lance, formerly an editor
at Nature Methods Group Leader - cell biology,
Ivy Editing
Author We believe that circulating TSH receptor
antibody is not essential for the diagnosis of
Graves disease, and therefore did not include it
in the original manuscript. The information has
been added to the revised ms.
E-mail paper_at_theivyediting.com
Tel 021-61390110
83
Ross Baldessarini, MD, DSc Professor, Harvard
Medical School Editorial Advisor, Ivy Editing
Lesson 3 - Do NOT teach reviewers
E-mail paper_at_theivyediting.com
Tel 021-61390110
84
James ODonnell, PhD Professor, West Virginia
Univ Editorial Advisor, Ivy Editing
Lesson 3 - Do NOT volunteer information
E-mail paper_at_theivyediting.com
Tel 021-61390110
85
Bryan Hurley, PhD Assistant Professor, Harvard
Medical School Group Leader - immunology, Ivy
Editing
Reviewer The D4 receptor assay is invalid. The
radioligand 3Hnemonapride labels all members of
the D2-like receptors, including the D2, D3, and
D4 receptors. Admittedly, the authors made an
attmpt to occlude binding of 3Hnemonapride to
D2 and D3 receptors with raclopride. However, the
D2 receptor is far more abundant than the D4
receptor. As a result, the claim that this is a
D4 receptor assay is invalid.
E-mail paper_at_theivyediting.com
Tel 021-61390110
86
Arne Nystuen, PhD Assistant Professor, Univ. of
Nebraska Group Leader - genetics, Ivy Editing
Reviewer The D4 receptor assay is invalid. The
radioligand 3Hnemonapride labels all members of
the D2-like receptors, including the D2, D3, and
D4 receptors. Admittedly, the authors made an
attmpt to occlude binding of 3Hnemonapride to
D2 and D3 receptors with raclopride. However, the
D2 receptor is far more abundant than the D4
receptor. As a result, the claim that this is a
D4 receptor assay is invalid.
E-mail paper_at_theivyediting.com
Tel 021-61390110
87
Kai Sonntag, MD, PhD Assistant Professor, Harvard
Medical School Group Leader - neuroscience, Ivy
Editing
E-mail paper_at_theivyediting.com
Tel 021-61390110
88
Anne ODonnell, MD, PhD Boston Children
Hospital Group Leader - clinical studies, Ivy
Editing
3Hnemonapride
D2
D3
D4
E-mail paper_at_theivyediting.com
Tel 021-61390110
89
Bo Cui, MD, PhD Deputy Editor-in-Chief, J Biomed
Res Group Leader - tumor biology, Ivy Editing
3Hnemonapride
raclopride
D2
D3
D4
E-mail paper_at_theivyediting.com
Tel 021-61390110
90
Jesse Potash, PhD Free-lance, formerly an editor
at Nature Methods Group Leader - cell biology,
Ivy Editing
3Hnemonapride
raclopride
D2
D3
D4
E-mail paper_at_theivyediting.com
Tel 021-61390110
91
Ross Baldessarini, MD, DSc Professor, Harvard
Medical School Editorial Advisor, Ivy Editing
We understand the reviewer concern. The D2
receptor is indeed far more abundant than the D4
receptor in rat brain (roughly 100 fold ref 1).
We did, however, carried out a carefully designed
experiment in purified receptors and demonstrated
that at 300 nM (the concentration used in our
assay), raclopride eliminates gt99.9 of the
binding of 3Hnemonapride to D2 receptor without
affecting its binding to D4 receptor. As a
result, we believe gt90 of the signal in our
assay represents the D4 receptor. Such data were
published in a previous report from this
laboratory (ref 2), and comfirmed by a group led
by Nemoroff and colleagues (ref 3). Based on
these findings, we believe ..
E-mail paper_at_theivyediting.com
Tel 021-61390110
92
James ODonnell, PhD Professor, West Virginia
Univ Editorial Advisor, Ivy Editing
We understand the reviewer concern. The D2
receptor is indeed far more abundant than the D4
receptor in rat brain (roughly 100 fold ref 1).
We did, however, carried out a carefully designed
experiment in purified receptors and demonstrated
that at 300 nM (the concentration used in our
assay), raclopride eliminates gt99.9 of the
binding of 3Hnemonapride to D2 receptor without
affecting its binding to D4 receptor. As a
result, we believe gt90 of the signal in our
assay represents the D4 receptor. Such data were
published in a previous report from this
laboratory (ref 2), and comfirmed by a group led
by Nemoroff and colleagues (ref 3). Based on
these findings, we believe ..
E-mail paper_at_theivyediting.com
Tel 021-61390110
93
Bryan Hurley, PhD Assistant Professor, Harvard
Medical School Group Leader - immunology, Ivy
Editing
We understand the reviewer concern. The D2
receptor is indeed far more abundant than the D4
receptor in rat brain (roughly 100 fold ref 1).
We did, however, carried out a carefully designed
experiment in purified receptors and demonstrated
that at 300 nM (the concentration used in our
assay), raclopride eliminates gt99.9 of the
binding of 3Hnemonapride to D2 receptor without
affecting its binding to D4 receptor. As a
result, we believe gt90 of the signal in our
assay represents the D4 receptor. Such data were
published in a previous report from this
laboratory (ref 2), and comfirmed by a group led
by Nemoroff and colleagues (ref 3). Based on
these findings, we believe ..
E-mail paper_at_theivyediting.com
Tel 021-61390110
94
Arne Nystuen, PhD Assistant Professor, Univ. of
Nebraska Group Leader - genetics, Ivy Editing
We understand the reviewer concern. The D2
receptor is indeed far more abundant than the D4
receptor in rat brain (roughly 100 fold ref 1).
We did, however, carried out a carefully designed
experiment in purified receptors and demonstrated
that at 300 nM (the concentration used in our
assay), raclopride eliminates gt99.9 of the
binding of 3Hnemonapride to D2 receptor without
affecting its binding to D4 receptor. As a
result, we believe gt90 of the signal in our
assay represents the D4 receptor.
E-mail paper_at_theivyediting.com
Tel 021-61390110
95
Kai Sonntag, MD, PhD Assistant Professor, Harvard
Medical School Group Leader - neuroscience, Ivy
Editing
We understand the reviewer concern. The D2
receptor is indeed far more abundant than the D4
receptor in rat brain (roughly 100 fold ref 1).
We did, however, carried out a carefully designed
experiment in purified receptors and demonstrated
that at 300 nM (the concentration used in our
assay), raclopride eliminates gt99.9 of the
binding of 3Hnemonapride to D2 receptor without
affecting its binding to D4 receptor. As a
result, we believe gt90 of the signal in our
assay represents the D4 receptor. Such data were
published in a previous report from this
laboratory (ref 2), and comfirmed by a group led
by Nemoroff and colleagues (ref 3). Based on
these findings, we believe ..
E-mail paper_at_theivyediting.com
Tel 021-61390110
96
Anne ODonnell, MD, PhD Boston Children
Hospital Group Leader - clinical studies, Ivy
Editing
Lesson 4 - Argue respectfully, with support
(data, published papers)
E-mail paper_at_theivyediting.com
Tel 021-61390110
97
Bo Cui, MD, PhD Deputy Editor-in-Chief, J Biomed
Res Group Leader - tumor biology, Ivy Editing
Lesson 4 - Argue respectfully, with support
(data, published papers) and clear
reasoning
E-mail paper_at_theivyediting.com
Tel 021-61390110
98
Jesse Potash, PhD Free-lance, formerly an editor
at Nature Methods Group Leader - cell biology,
Ivy Editing
Journal Selection - building a successful career
E-mail paper_at_theivyediting.com
Tel 021-61390110
99
Ross Baldessarini, MD, DSc Professor, Harvard
Medical School Editorial Advisor, Ivy Editing
Journal Selection - impact factor
E-mail paper_at_theivyediting.com
Tel 021-61390110
100
James ODonnell, PhD Professor, West Virginia
Univ Editorial Advisor, Ivy Editing
Journal Selection - impact factor -
penetration
E-mail paper_at_theivyediting.com
Tel 021-61390110
101
Bryan Hurley, PhD Assistant Professor, Harvard
Medical School Group Leader - immunology, Ivy
Editing
Journal Selection - impact factor -
penetration
Those who can influence your future
E-mail paper_at_theivyediting.com
Tel 021-61390110
102
Arne Nystuen, PhD Assistant Professor, Univ. of
Nebraska Group Leader - genetics, Ivy Editing
1)???4???????????
E-mail paper_at_theivyediting.com
Tel 021-61390110
103
Kai Sonntag, MD, PhD Assistant Professor, Harvard
Medical School Group Leader - neuroscience, Ivy
Editing
1)???4??????????? 2)???4????????????
E-mail paper_at_theivyediting.com
Tel 021-61390110
104
Anne ODonnell, MD, PhD Boston Children
Hospital Group Leader - clinical studies, Ivy
Editing
Dopamine D4 receptors in motor hyperactivity
induced by neonatal 6-hydroxydopamine lesions in
rats ???? ???? -------------------------
----------------------------------------
PNAS Journal of Neuroscience
Neuropsychopharmacology
Behavioral Neuroscience
------------------------------------------------
----------------------------
E-mail paper_at_theivyediting.com
Tel 021-61390110
105
Bo Cui, MD, PhD Deputy Editor-in-Chief, J Biomed
Res Group Leader - tumor biology, Ivy Editing
Dopamine D4 receptors in motor hyperactivity
induced by neonatal 6-hydroxydopamine lesions in
rats ???? ??? ???? ---------------------
--------------------------------------------
PNAS Journal of
Neuroscience
Neuropsychopharmacology
Behavioral Neuroscience
------------------------------------------------
----------------------------
E-mail paper_at_theivyediting.com
Tel 021-61390110
106
(No Transcript)
107
Jesse Potash, PhD Free-lance, formerly an editor
at Nature Methods Group Leader - cell biology,
Ivy Editing
Zhang K, Tarazi FI, Baldessarini RJ Role of
dopamine D4 receptors in motor hyperactivity
induced by neonatal 6-hydroxydopamine lesions in
rats. Neuropsychopharmacology, 25624632,
2001 Zhang K, Tarazi FI, Davids E, Baldessarini
RJ Plasticity of dopamine D4 receptors in rat
forebrain Temporal association with motor
hyperactivity following neonatal
6-hydroxydopamine lesioning. Neuropsychopharmacolo
gy, 26625633, 2002
E-mail paper_at_theivyediting.com
Tel 021-61390110
108
(No Transcript)
109
Ross Baldessarini, MD, DSc Professor, Harvard
Medical School Editorial Advisor, Ivy Editing
Zhang K, Tarazi FI, Baldessarini RJ Role of
dopamine D4 receptors in motor hyperactivity
induced by neonatal 6-hydroxydopamine lesions in
rats. Neuropsychopharmacology, 25624632,
2001 Zhang K, Tarazi FI, Davids E, Baldessarini
RJ Plasticity of dopamine D4 receptors in rat
forebrain Temporal association with motor
hyperactivity following neonatal
6-hydroxydopamine lesioning. Neuropsychopharmacolo
gy, 26625633, 2002 Zhang K, Grady CJ, Tsapakis
EM, Andersen SL, Tarazi FI, Baldessarini RJ
Regulation of working memory by dopamine D4
receptor in rats. Neuropsychopharmacology,
2916371647, 2004
E-mail paper_at_theivyediting.com
Tel 021-61390110
110
James ODonnell, PhD Professor, West Virginia
Univ Editorial Advisor, Ivy Editing
Dear Dr. Zhang I am writing this letter to
invite you to join the Pharmacology for
Neuropsychiatric Disorders Small Business study
section of the National Institutes of Health.
Jerome R. Wujek, PhD Scientific Review
Administrator National Institutes of Health
Center for Scientific Review
E-mail paper_at_theivyediting.com
Tel 021-61390110
111
Bryan Hurley, PhD Assistant Professor, Harvard
Medical School Group Leader - immunology, Ivy
Editing
Editing2.0 - online - ??????
E-mail paper_at_theivyediting.com
Tel 021-61390110
112
(No Transcript)
113
(No Transcript)
114
Contact us www.theivyediting.com Tel
021-61390110 paper_at_theivyediting.com
Write a Comment
User Comments (0)
About PowerShow.com